Take a look at some of Monday's midday movers:
Amgen - The biotechnology company rose after it said its blood-cancer drug met its main goal in a late-stage trial.
BioCryst Pharmaceuticals - The drug developer advanced as it's currently developing a drug to treat a broad spectrum of viruses including Ebola, with the partial support of the National Institutes of Health.
Durata Therapeutics - The drug maker gained after saying its Dutch subsidiary had entered into an agreement with Italy's Angelini to market its antibiotic to treat skin infections.
GlaxoSmithKline - The drug developer edged higher after Reuters reported Express Scripts Holdings, the nation's biggest pharmacy benefit manager, had decided to reinstate its lung-drug Advair as an approved drug in 2015.
Groupon - The online provider of daily deals surged a day before it releases second-quarter earnings.
Impax Laboratories - The pharmaceutical company fell after saying the U.S. Food and Drug Administration had re-inspected its manufacturing plant in Hayward, Calif.
Loews - The conglomerate declined after reporting a lower-than-expected quarterly profit.
Michael Kors Holdings - The apparel retailer fell after saying it expects margins to shrink in 2014.
Pike - The provider of engineering and other services to the energy industry rose after agreeing to be taken private.
T-Mobile US - The wireless carrier advanced after Evercore said there was plenty of upside for the stock even without a sale.
Tekmira Pharmaceuticals - Shares fell after CNN reported another company could be the first to have its Ebola treatment used against an outbreak in Africa.
Trex Company - The provider of construction supplies jumped after tallying better-than-expected quarterly profit.
Walgreen - The drugstore chain climbed after saying it was replacing its chief financial officer ahead of a decision on whether to move its headquarters overseas to reduce its U.S. tax bill.
Walt Disney - The entertainment company rose after a strong opening weekend of its "Guardians of the Galaxy" movie.
—By CNBC's Rich Fisherman.
Questions? Comments? Email us at firstname.lastname@example.org